688526.SH
科前生物
SSE · Healthcare · Biotechnology · CN
CNY 12.97
−0.92%Year over year
Reported trailing growth
- Revenue
- -5.1%
- EBITDA
- —
- EBIT
- -3.5%
- EPS
- -3.5%
- Free cash flow
- -8.9%
- Operating cash flow
- -5.2%
Forward estimates
Based on analyst estimates
- Revenue
- -19.1%
- EBITDA
- -8.2%
- EPS
- +49.9%
Three-year CAGR
- Revenue
- -1.7%
- EBITDA
- +1.8%
- EBIT
- +1.2%
- Net income
- +0.7%
- EPS
- +0.8%
- Free cash flow
- +2.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026